Redx Pharma records promising pre-clinical data for potential fibrosis treatment

Writer, Stock Market Wire
Tuesday, February 12, 2019 - 09:22

Redx Pharma said it had recorded promising pre-clinical efficacy data for a lead fibrosis treatment compound.

New data was produced from three independent pre-clinical animal models of lung, kidney and liver fibrosis, all testing the company lead ROCK2 compound.

The data showed it was able to suppress collagen deposition and pathways associated with fibrosis, indicating that selective ROCK2 inhibition could have an impact on established fibrosis.

The data would be presented in more detail later in 2019 at a scientific meeting.

Redx said it planned to nomiate a drug candidate for the ROCK2 programme by mid 2019, following final safety evaluations.

If nominated for development, it would be developed as an orally-administered treatment, with first-in-man studies commencing in 2020.

At 9:22am: (LON:REDX) Redx Pharma Plc share price was +1.25p at 8p

Related content

Redx Pharma gets UK regulator nod for cancer treatment trial

Cancer and fibrosis focused Redx Pharma said UK regulators had granted approval for the company to re-commence a trial of a cancer treatment.

Permission was...

Mon, 21/01/2019 - 08:11

Redx Pharma presents positive pre-clinical data on fibrosis treatment

Redx Pharma said it had presented pre-clinical data at a US conference for a new drug development candidate to treat idiopathic pulmonary fibrosis, a long...

Fri, 30/11/2018 - 09:17

Redx Pharma swings to loss; to kick off new clinical trial in 2019

Oncology and fibrosis-focused drug developer Redx Pharma swung to an annual loss after emerging from administration in November and slashing its headcount.

The company also...

Mon, 19/11/2018 - 08:17

Which small cap pharma firms make a profit?

Typically people invest in small cap biotechnology and pharmaceutical stocks in the hope they can enjoy returns of many times their initial investment as the...

Thu, 15/11/2018 - 00:00

Redx Pharma presents cancer treatment data at Glasgow conference

Redx Pharma said it had presented positive data from pre-clinical studies evaluating a cancer treatment during a poster session at an industry conference in Glasgow....

Mon, 05/11/2018 - 13:59